Episode 55: CHAPTER-3 , Pharvaris Oral Prophylaxis Phase 3 Study

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/e8/8f/6e/e88f6e5c-972d-6b3d-6b41-cac114cb4bce/mza_8016163048844739500.jpg/600x600bb.jpg

HAE Speaks

US HAEA

62 episodes

4 days ago

HAE Speaks, a podcast series on important Hereditary Angioedema (HAE) topics. Listen to patients, caregivers, and medical professionals discuss strategies to manage stress, prepare for a visit with your HAE specialist, care for a loved one with HAE, what to expect when you are newly diagnosed, the road to treatment, and much more.

Non-Profit

Business

RSS

All content for HAE Speaks is the property of US HAEA and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Non-Profit

Business

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/5143322/5143322-1591037698960-615a3563e1963.jpg

Episode 55: CHAPTER-3 , Pharvaris Oral Prophylaxis Phase 3 Study

HAE Speaks

12 minutes 30 seconds

4 months ago

Episode 55: CHAPTER-3 , Pharvaris Oral Prophylaxis Phase 3 Study

In this episode of the HAE Speaks Podcast, Dr. Raffi Tachdjian (UCLA) and Pharvaris discuss the HAE CHAPTER-3 Study — a new HAE attack prevention trial currently enrolling. The study explores the safety and effectiveness of deucrictibant, an investigational once-daily oral treatment aimed at preventing HAE attacks.

Thank you to Pharvaris for sponsoring this episode of the HAE Speaks Podcast!